Loading clinical trials...
Loading clinical trials...
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Conditions
Interventions
MBG453
Azacitidine
+2 more
Locations
15
United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
Arizona Oncology Associates
Tucson, Arizona, United States
SCRI-Colorado Blood Cancer Institute
Denver, Colorado, United States
Yale University School Of Medicine
New Haven, Connecticut, United States
Advent Health Orlando
Orlando, Florida, United States
Uni of Massachusetts Medical Center
Worcester, Massachusetts, United States
Start Date
March 17, 2022
Primary Completion Date
October 26, 2023
Completion Date
September 1, 2024
Last Updated
October 16, 2025
NCT03520647
NCT05143996
NCT05534620
NCT02143830
NCT03613532
NCT02790515
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions